Prevalence and recovery of dysphonia in COVID-19 patients requiring intensive care treatment

被引:1
|
作者
Clayton, Nicola A. [1 ,2 ,3 ,4 ,10 ]
Freeman-Sanderson, Amy [5 ,6 ,7 ,8 ,9 ]
Walker, Elizabeth [5 ,6 ]
机构
[1] Concord Repatriat Gen Hosp, Speech Pathol Dept, Sydney, NSW, Australia
[2] Concord Repatriat Gen Hosp, Intens Care Unit, Sydney, NSW, Australia
[3] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[4] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia
[5] Royal Prince Alfred Hosp, Speech Pathol Dept, Sydney, NSW, Australia
[6] Royal Prince Alfred Hosp, Intens Care Unit, Sydney, NSW, Australia
[7] Univ Technol Sydney, Grad Sch Hlth, Sydney, NSW, Australia
[8] George Inst Global Hlth, Crit Care Div, Sydney, NSW, Australia
[9] Monash Univ, Australian & New Zealand Intens Care Res Ctr ANZIC, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia
[10] Concord Repatriat Gen Hosp, Speech Pathol Dept, Bldg 42,Hosp Rd, Concord, NSW 2139, Australia
关键词
COVID-19; SARS-CoV2; Dysphonia; Critically ill; Recovery;
D O I
10.1016/j.aucc.2023.07.043
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Dysphonia and laryngeal pathology are considerable issues in patients hospitalised with COVID-19 with prevalence rates cited between 29% and 79%. Most studies currently are limited to reporting single-institution data with many retrospective. Objectives: The aims of this study were to prospectively explore the following: (i) prevalence; (ii) treatment; and (iii) recovery pattern and outcomes for dysphonia, in patients with COVID-19 requiring intensive care unit (ICU) treatment. Methods: Patients admitted to 26 ICUs over 12 months, diagnosed with COVID-19, treated for survival, and seen by speech-language pathology for clinical voice assessment were considered. Demographic, medical, speech-language pathology treatment, and voice outcome data (grade, roughness, breathiness, asthenia, strain [GRBAS]) were collected on initial consultation and continuously monitored throughout the hospital admission. Findings: Two-hundred and thirty five participants (63% male, median age = 58 yrs) were recruited. Median mechanical ventilation duration and ICU and hospital lengths of stay (LOSs) were 16, 20, and 42 days, respectively. Dysphonia prevalence was 72% (170/235), with 22% (38/170) exhibiting profound impairment (GRBAS score = 3). Of those with dysphonia, rehabilitation was provided in 32% (54/170) cases, with dysphonia recovery by hospital discharge observed in 66% (112/170, median duration = 35 days [interquartile range = 21-61 days]). Twenty-five percent (n = 42) of patients underwent nasendoscopy: oedema (40%, 17/42), granuloma (31%, 13/42), and vocal fold palsy/paresis (26%, 11/42). Presence of dysphonia was inversely associated with the number of intubations (p = 0.002), intubation duration (p = 0.037), ICU LOS (p = 0.003), and hospital LOS (p = 0.009). Conversely, duration of dysphonia was positively associated with the number of intubations (p = 0.012), durations of intubation (p = 0.000), tracheostomy (p = 0.004), mechanical ventilation (p = 0.000), ICU LOS (p = 0.000), and hospital LOS (p = 0.000). More severe dysphonia was associated with younger age (p = 0.045). Proning was not associated with presence (p = 0.075), severity (p = 0.164), or duration (p = 0.738) of dysphonia. Conclusions: Dysphonia and laryngeal pathology are common in critically ill patients with COVID-19 and are associated with younger age and protracted recovery in those with longer critical care interventions. Crown Copyright (c) 2023 Published by Elsevier Ltd on behalf of Australian College of Critical Care Nurses Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).
引用
收藏
页码:151 / 157
页数:7
相关论文
共 50 条
  • [41] Continuous renal replacement therapy in intensive care patients with COVID-19; survival and renal recovery
    Eriksson, Karin E.
    Campoccia-Jalde, Francesca
    Rysz, Susanne
    Rimes-Stigare, Claire
    JOURNAL OF CRITICAL CARE, 2021, 64 : 125 - 130
  • [42] Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission
    Oliva, A.
    Ceccarelli, G.
    Borrazzo, C.
    Ridolfi, M.
    'Ettorre, G. D.
    Alessandri, F.
    Ruberto, F.
    Pugliese, F.
    Raponi, G. M.
    Russo, A.
    Falletta, A.
    Mastroianni, C. M.
    Venditti, M.
    INFECTION, 2021, 49 (05) : 965 - 975
  • [43] Prevalence of Dysphonia in Non hospitalized Patients with COVID-19 in Lombardy, the Italian Epicenter of the Pandemic
    Cantarella, Giovanna
    Alde, Mirko
    Consonni, Dario
    Zuccotti, Gianvincenzo
    Di Berardino, Federica
    Barozzi, Stefania
    Bertoli, Simona
    Battezzati, Alberto
    Zanetti, Diego
    Pignataro, Lorenzo
    JOURNAL OF VOICE, 2023, 37 (04) : 605 - 609
  • [44] Longitudinal Assessment of Health and Quality of Life of COVID-19 Patients Requiring Intensive Care-An Observational Study
    Erber, Johanna
    Wiessner, Johannes R.
    Zimmermann, Gregor S.
    Barthel, Petra
    Burian, Egon
    Lohofer, Fabian
    Martens, Eimo
    Mijocevic, Hrvoje
    Rasch, Sebastian
    Schmid, Roland M.
    Spinner, Christoph D.
    Braren, Rickmer
    Schneider, Jochen
    Lahmer, Tobias
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [45] Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission
    A. Oliva
    G. Ceccarelli
    C. Borrazzo
    M. Ridolfi
    G. D.’Ettorre
    F. Alessandri
    F. Ruberto
    F. Pugliese
    G. M. Raponi
    A. Russo
    A. Falletta
    C. M. Mastroianni
    M. Venditti
    Infection, 2021, 49 : 965 - 975
  • [46] General principles of care for patients with COVID-19 in the intensive care unit
    Parizkova, Cerna R.
    Mach, D.
    ANESTEZIOLOGIE A INTENZIVNI MEDICINA, 2020, 31 (1-2): : 49 - 50
  • [47] Treatment of severe COVID-19 courses in intensive care medicine
    Wiesner, O.
    Busch, M.
    David, S.
    INTERNIST, 2020, 61 (08): : 804 - 811
  • [48] Treatment of severe COVID-19 courses in intensive care medicine
    Busch, M.
    Wiesner, O.
    David, S.
    GASTROENTEROLOGE, 2020, 15 (06): : 477 - 486
  • [49] EVALUATION OF TOCILIZUMAB FOR COVID-19 TREATMENT IN THE INTENSIVE CARE UNIT
    Dehne, Lauren
    Liao, Siyun
    Takieddine, Sheila
    Droege, Chris
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 208 - 208
  • [50] Importance of hyperglycemia in COVID-19 intensive-care patients: Mechanism and treatment strategy
    Mirzaei, Fatemeh
    Khodadadi, Iraj
    Vafaei, Seyyed Alireza
    Abbasi-Oshaghi, Ebrahim
    Tayebinia, Heidar
    Farahani, Farhad
    PRIMARY CARE DIABETES, 2021, 15 (03) : 409 - 416